Genetic heterogeneity in corpus callosum agenesis

Monica-Cristina Pânzaru1, Setalia Popa1*, Ancuta Lupu2†, Cristina Gavrilovici2†, Vasile Valeriu Lupu2* and Eusebiu Vlad Gorduza1

1Department of Medical Genetics, Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania, 2Department of Pediatrics, Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania

The corpus callosum is the largest white matter structure connecting the two cerebral hemispheres. Agenesis of the corpus callosum (ACC), complete or partial, is one of the most common cerebral malformations in humans with a reported incidence ranging between 1.8 per 10,000 livebirths to 230–600 per 10,000 in children and its presence is associated with neurodevelopmental disability. ACC may occur as an isolated anomaly or as a component of a complex disorder, caused by genetic changes, teratogenic exposures or vascular factors. Genetic causes are complex and include complete or partial chromosomal anomalies, autosomal dominant, autosomal recessive or X-linked monogenic disorders, which can be either de novo or inherited. The extreme genetic heterogeneity, illustrated by the large number of syndromes associated with ACC, highlight the underlying complexity of corpus callosum development. ACC is associated with a wide spectrum of clinical manifestations ranging from asymptomatic to neonatal death. The most common features are epilepsy, motor impairment and intellectual disability. The understanding of the genetic heterogeneity of ACC may be essential for the diagnosis, developing early intervention strategies, and informed family planning. This review summarizes our current understanding of the genetic heterogeneity in ACC and discusses latest discoveries.

KEYWORDS

corpus callosum, agenesis, heterogeneity, chromosomal anomalies, monogenic

Introduction

The corpus callosum (CC) is the greatest forebrain commissure in humans, containing approximately two hundred million callosal axons, and its major role is to integrate and transfer information between the two hemispheres. This interhemispheric communication is important for the functions of the cerebral cortex such as integration of sensory, motor, and visuomotor information, abstract reasoning, language processing and management of social and emotional stimuli (Paul et al., 2007; Edwards et al., 2014; Palmer and Mowat 2014; De Leon Reyes et al., 2020). The adult CC is anatomically divided into several regions: rostrum, genu, body, isthmus, and splenium. The rostrum and genu link the frontal and prefrontal regions of the cerebral cortex, the middle part
connects the motor, somatosensory, and parietal regions, while the splenium conjoins the temporal and occipital cortices on both sides (De Leon Reyes et al., 2020). The aim of this paper is to present the genetic abnormalities involved in the etiology of ACC and their relationship to CC development. We also focused on the suggestive associated features and the benefits of genetic testing for valuable prognostic information and the development of personalized management.

Literature search strategies and data collection

The data synthesized and presented in this review was obtained by examining the literature (OMIM, PubMed, MEDLINE, Google Scholar databases) and using the following keywords: corpus callosum agenesis, corpus callosal disorders, corpus callosum development, genetic heterogeneity, genetic abnormalities, chromosomal abnormalities, monogenic disorders, chromosomal microarray analysis (CMA), whole exome sequencing (WES), whole genome sequencing (WGS), next generation sequencing (NGS). Only English language papers published within the previous 10 years were considered for this review. A narrative synthesis was generated for the main outcome. The Online Mendelian Inheritance in Man (OMIM) database was used as the reference for gene and mutation symbols.

Development of the corpus callosum

CC development begins around the 12th week of gestation, and follows well-orchestrated events: neuronal and glial proliferation, neuronal migration and specification, midline patterning, axonal growth and guidance, and post-guidance refinement. The CC is complete and easily recognized by the 14–15th week of gestation whereas the splenium becomes prominent by the 18–19th week of gestation. CC development is a complex process and involves many pathways such as Semaphorin/Plexin/Neuropilin, Slit/Robo, Eph/Ephrin, Netrin/DCC/Unc5, Wnt/Ryk and FGF8/MAPK (De Leon Reyes et al., 2020; Ku and Torii 2020). Some molecules act as nodes of a transcriptional network regulating CC formation. Special AT-rich sequence-binding protein (SATB2), a nuclear matrix DNA-binding protein, involved in transcriptional regulation and chromatin remodeling, plays a central role in development of callosal projections. SATB2 participates in the direct transcriptional repression of CTIP2 gene (De Leon Reyes et al., 2020). Expressions of SATB2 and CTIP2 genes are influenced by histone methylation (e.g. DOT1L), calcium signaling, and other mechanisms (Franz et al., 2019). Molecules from Netrin-1 signaling pathway also interact with SATB2 gene: DCC gene (OMIM 120470) is directly downregulated by SATB2, while UNCS5 gene (OMIM 603610) is directly upregulated and downregulated by SATB2 and CTIP2 (Srinivasan et al., 2012). The heat shock cognate protein HSC70 is required for the stability of the DCC/TRIO signaling complex and to mediate axon guidance (DeGeer et al., 2015). Netrin-1 can trigger either attraction or repulsion of the axon depending on the receptor it binds. SATB2 also directly upregulates the expression of EPHA4 gene (OMIM 602118), a member of Ephi/ephrin pathways (Srinivasan et al., 2012). Transcription factors FOXG1 promotes SATB2 gene expression and directly represses ROBO1 gene (roundabout guidance receptor 1) (OMIM 602430) and SLIT3 gene (OMIM 603745) expression (Cargnin et al., 2018). Slit molecules bind Robo receptors and act as a repulsive axon guidance cue (Gonda et al., 2020). Amyloid precursor protein (APP) serves as a Slit receptor and mediates axon repulsion (Wang et al., 2017). Semaphorins (SEMA3A and SEMA3C), also have essential roles in corpus callosum development, through signaling mediated by their coreceptors Neuropilin-1 and Plexin-A1 (Hossain et al., 2019).

Agenesis of the corpus callosum - epidemiology and causes

Many factors could disrupt this complex developmental process and lead to agenesis of the corpus callosum (ACC) also known as corpus callosal disorders. ACC, complete or partial, is one of the most common cerebral anomaly in humans with a reported incidence of 1.8 per 10,000 livebirths, but a significant percentage of prenatally diagnosed cases result in termination of pregnancy or spontaneous abortion (Glass et al., 2008; Weise et al., 2019). The prevalence is higher in children with developmental disabilities: 230–600 per 10,000 (Schell-Apacik et al., 2008; Palmer and Mowat 2014). An increased risk for male gender and preterm birth has been reported (Ballardini et al., 2018). ACC may occur as an isolated anomaly or as a component of a complex disorder, caused by genetic abnormalities, teratogenic exposures or vascular factors. The prevalence of associated anomalies at birth varies considerably among studies, between 39.6% and 86.5% (Glass et al., 2008; Szabo et al., 2011; Stoll et al., 2019). According to Morris et al., 52% of ACC occur as an isolated condition, 25% have associated anomalies (unknown etiology), and 23% are syndromic (with chromosomal, monogenic or teratogenic causes) (Morris et al., 2019). The most common associated anomalies involve the musculoskeletal, the central nervous, the cardiovascular, the urogenital, and the digestive
The central nervous system anomalies include hydrocephalus, cerebellar hypoplasia, periventricular nodular heterotopia, polymicrogyria, microgyria, and lissencephaly (Glass et al., 2008; Ballardini et al., 2018; Stoll et al., 2019). In cases with hydrocephalus, the differentiation between arrested ventriculomegaly and progressive hydrocephalus is essential for appropriate management. Based on neurological, ophthalmological, and psychometric evaluations, this distinction is very difficult. Radiological markers (frontal-occipital horn ratio, apparent diffusion coefficient, and cerebral blood flow) and intracranial pressure monitoring are very useful diagnostic tools (Leliefeld et al., 2010; Hurni et al., 2018). Genetic causes include complete or partial chromosomal anomalies, autosomal dominant, autosomal recessive or X-linked monogenic disorders, de novo or inherited. Several selected syndromes are discussed in more detail concerning their associated anomalies. Multiple other genetic abnormalities are summarized in Tables 1 and 2.

### Chromosomal abnormalities

Chromosomal abnormalities have been identified in 4.81–17.8% of ACC; especially when associated congenital anomalies are present. The reported complete aneuploidies include: trisomy 18, 13, 8 in mosaic, 21 and X monosomy (Glass et al., 2008; O’Driscoll et al., 2010; Palmer and Mowat 2014; D’Antonio et al., 2016). Callosal abnormalities are also associated with partial chromosomal anomalies, the most common: 8p inverted duplication/deletion syndrome, 1q43q44, 6q27 and 17q21.31 microdeletions are characterized below. However, many copy number variants have been reported in cases with ACC (Table 1).

#### 1q43q44 microdeletion syndrome

1q43q44 microdeletion syndrome (OMIM 621337) is a disorder characterized by moderate to severe intellectual disability with limited or no expressive speech, microcephaly, agenesis/hypogenesis of the CC, seizures, suggestive facial dysmorphism (round face, prominent forehead, hypertelorism, epicanthal folds, flat nasal bridge, and malformed and low-set ears), and hand and foot anomalies. Ballif et al. proposed a 75 Kb critical region for ACC that contains ZBTB18 gene (OMIM 608433), which encodes a transcriptional repressor of key genes involved in neuronal development (Ballif et al., 2012). The phenotypic heterogeneity (no ACC) in cases with critical region deletion has been explained by incomplete penetrance or variable expressivity. Depienne et al. considered that ACC is also influenced by the alteration of neighboring genes especially HNRNPU (OMIM 617391) (Ballif et al., 2012; de Munnik et al., 2014; Cohen et al., 2017; Depienne et al., 2017).

### TABLE 1 Partial chromosomal anomalies and candidate genes associated with ACC (Dobyns 1996; Schell-Apacik et al., 2008; O’Driscoll et al., 2010; Edwards et al., 2014). The italic values represent genes.

| Region          | Type | OMIM   | Candidate gene |
|-----------------|------|--------|----------------|
| 1p36            | del  | 600997 | EPHB2         |
|                 |      | 164780 | SKI           |
|                 |      | 137165 | GABRD         |
|                 |      | 176982 | PRKCZ         |
|                 |      |        | TMEM52        |
|                 |      |        | CFAP74        |
| 2q14            | del  | 601428 | RNU4ATAC      |
|                 |      | 165230 | GLI2          |
|                 |      | 160519 | TNNTA5P       |
| 2q31-33         | del  | 608148 | SATB2         |
|                 |      | 602188 | EPHA4         |
|                 |      | 123810 | CREB1         |
| 3q24            | del  | 600470 | ZIC1          |
| 4p16.3          | del  | 134934 | FGFR3         |
|                 |      | 602618 | CTRP1         |
|                 |      | 616918 | PEGG          |
| 5p13-p15        | dup  | 601893 | TRIO          |
| 6p25            | dup  | 601090 | FOXC1         |
|                 |      | 603250 | FOXF2         |
|                 |      | 612788 | FOXQ1         |
|                 |      | 615101 | TUBB2A        |
|                 |      | 612850 | TUBB2B        |
| 9q34.3          | del  | 607001 | EHM1T         |
| 11q 25          | dup  | 116930 | NCAM1         |
|                 |      | 608774 | ANK1          |
| 13q14           | del  | 604354 | NUP1P1        |
|                 |      | 603850 | PCDH8         |
|                 |      | 611760 | PCDH17        |
| 13q32.3-q33.1   | del  | 603073 | ZIC2          |
|                 |      | 617896 | ZIC5          |
| 13q34           | dup  | 120130 | COL4A1        |
|                 |      | 120090 | COL4A2        |
|                 |      | 605477 | ARHGFE7       |
|                 |      | 602148 | SOX1          |
|                 |      | 605868 | ATP11A        |
| 14q11-q22       | del  | 164874 | FOXG1         |
| 15q24           | del  | 118485 | CVP1A1        |
|                 |      | 607961 | SEMA7A        |
|                 |      | 609585 | CPLX3         |
|                 |      | 612457 | ARID3B        |
|                 |      | 610745 | STRA6         |
|                 |      | 607776 | SINS1A        |
| 16q24.3         | del  | 603464 | CDK10         |
|                 |      | 611932 | ANKRD61       |
| 17p13.3         | del  | 605066 | YWHAE         |
|                 |      | 601545 | PEA4H1B1      |
|                 |      | 603527 | DPH1          |
| 18q21.2         | del  | 120470 | DCC           |
| 21q22.1-q22.3   | del/dup | 600855 | DYRKA1       |
|                 |      | 104760 | APP           |
| 22q11.2         | del/dup | 116790 | COMT          |
|                 |      | 601754 | UFDL          |
|                 |      | 601180 | RANBP1        |
| Xp22            | del  | 300552 | MIDD1         |
|                 |      | 300118 | ARHGAP6       |
| Xq27.3-q28      | dup  | 300005 | MECP2         |
|                 |      | 300017 | FLNA          |
TABLE 2 Monogenic syndromes associated with ACC (Edwards et al., 2014; Hofman et al., 2020). The italic values represent genes.

| Disease                        | Gene   | Location | Phenotype                                                                                                                                                                                                 | OMIM  |
|-------------------------------|--------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|
| **Autosomal dominant**        |        |          |                                                                                                                                                                                                          |       |
| Mowat Wilson                  | ZEB2   | 2q22.3   | Facial dysmorph (widely spaced eyes, broad eyebrows with a medial flare, low-hanging columella, prominent or pointed chin, open-mouth expression, upturned earlobes with a central depression) intellectual disability, epilepsy, Hirschsprung disease, genitourinary anomalies, congenital heart defects, and eye anomalies |       |
| Primrose syndrome             | ZBTB20 | 3q13.31  | Macrocephaly, intellectual disability, enlarged and calcified external ears, facial dysmorph (high anterior hairline, sparse eyebrows, deeply set eyes, down slanting palpebral fissures, ptosis, high palate, broad jaw), distal muscle wasting and altered glucose metabolism |       |
| Sotos syndrome                | NSD1   | 5q35.3   | Overgrowth, advanced bone age, learning disability, facial dysmorphism (long narrow face, prominent forehead, sparse frontotemporal hair, malar flushing, pointed chin)                                            |       |
| Greig cephalo-poly syndactyly | GLI3   | 7p14.1   | Macrocephaly, frontal bossing, hypertelorism, pre- or post-axial polydactyly and cutaneous syndactyly                                                                                                             |       |
| Apert syndrome                | FGFR2  | 10q26.13 | Multisuture craniosynostosis, midface retrusion, syndactyly of the hands and feet                                                                                                                          |       |
| Rubinstein-Taybi syndrome     | CREBBP | 16p13.3  | Intellectual disability, broad thumbs and halluces, facial dysmorphism (highly arched eyebrows, long eyelashes, down slanting palpebral fissures, brachycephaly, flat nose)                                           |       |
| Coffin-Siris                  | ARID1A | 1p36.11  | Intellectual disability of varying degree, fifth-digit nul/distal phalanx hypoplasia/aglasia, hypertrichosis, sparse scalp hair, hypoplasia, facial dysmorphism (a wide mouth with thick, everted upper and lower lips, broad nasal bridge with broad nasal tip, thick eyebrows, and long eyelashes) |       |
| **Autosomal recessive**       |        |          |                                                                                                                                                                                                          |       |
| Chadley-McCullough syndrome   | GPSM2  | 1p13.3   | Early-onset, severe, bilateral sensorineural deafness, brain anomalies (cerebellar dysplasia, hydrocephalus, arachnoid cyst)                                                                                | 604213|
| Fumarase deficiency           | FH     | 1q42.1   | Early-onset hypotonia, severe psychomotor retardation, brain abnormalities (cerebral atrophy, ventriculomegaly), seizures, feeding difficulties, increased excretion of fumaric acid in urine                                        | 606812|
| Donnai-Barrow syndrome        | LRP2   | 2q31.1   | Ocular anomalies (high myopia, retinal detachment, progressive vision loss), sensorineural hearing loss, proteinuria, facial dysmorphism (large anterior fontanelle, hypertelorism, enlarged globes, down slanting palpebral fissures, depressed nasal bridge, short nose), intellectual disability, congenital diaphragmatic hernia/omphalocele | 222448|
| Smith-Lemli-Opitz syndrome    | DHCR7  | 11q13.4  | Prenatal and postnatal growth retardation, microcephaly, intellectual disability, cleft palate, cardiac defects, genital anomalies in males, postaxial polydactyly, syndactyly of the 2nd and 3rd toes, facial dysmorphism (narrow forehead, ptosis, epicantus, a broad nasal bridge, short nasal root, antverted nares, micrognathia), elevated serum concentration of 7-dehydrocholesterol | 270400|
| Tentamny syndrome             | C12orf57 | 12p13.31 | Ocular coloboma, seizures, brain abnormalities (CC and thalamus)                                                                                                                                              | 615140|
| Vici syndrome                 | EPG5   | 18q12.3- | Oculocutaneous hypopigmentation, cataracts, progressive cardiomyopathy, variable immunodeficiency, intellectual disability, failure to thrive, myopathy                                                      | 242840|
| Fryns syndrome                | PGYN   | 18q21.33 | Diaphragmatic defect, facial dysmorphism, distal digital hypoplasia, pulmonary hypoplasia, and associated anomalies (polyhydramnios, cloudy corneas/microphthalmia, orofacial clefting, renal dysplasia/renal cortical cysts, and/or malformations involving the brain, cardiovascular system, gastrointestinal system, and/or genitalia) | 606097|
| Microcephaly, short stature, and polymicrogyria (MSSP) | RITTN | 18q22.2  | Microcephaly, intellectual disability, brain malformations (pachygyria, polymicrogyria, midline defects), seizures, microcephaly related craniofacial dysmorphism (sloping forehead, high and broad nasal bridge), short stature | 610436|

(Continued on following page)
**Interstitial inverted duplication 8p associated with 8pter deletion**

Interstitial inverted duplication 8p associated with 8pter deletion is a complex and rare chromosomal rearrangement. Clinical features include mild to severe intellectual disability, hypoplasia/agenesis of the CC, characteristic facial dysmorphism (prominent forehead, temporal baldness, antverted nostrils, eversion of the lower lip, large mouth and ears), skeletal anomalies (scoliosis/kyphosis), hypotonia, and congenital heart defects. The invdupdel (8p) consists of a deletion of the telomeric region (8p23-pter) followed by an intermediate intact fragment, and a proximal inverted duplication of variable size. Rearrangements are mediated by two highly repetitive regions: the olfactory receptor gene clusters or defensin repeat (ORDRs); the polymorphic 8p23 inversion between these clusters increases...
the susceptibility of 8p to rearrangements. The 8p23.2-pter region contains the genes ARHGEF10 (OMIM 608236) and CSMD1 (OMIM 608397), associated to central nervous system development (de Die-Smulders et al., 1995; Giglio et al., 2001; Garcia-Santiago et al., 2015; Redaelli et al., 2022).

6q27 microdeletion

6q27 deletion is associated with a variable phenotype including intellectual disability, seizure, hypotonia, brain malformations (ACC, periventricular nodular heterotopia (PNH), polymicrogyria, hydrocephalus, and cerebellar malformations), short neck and craniofacial dysmorphism (microcephaly, broad nose with prominent nasal root and bulbous nasal tip, large and low-set ears, and downturned mouth). Other commonly reported findings are: joint laxity, heart defects and retinal anomalies. The size of deletion varies between 0.4 Mb and 10.8 Mb and does not seem to correlate with phenotype severity, suggesting the existence of a minimal critical region. Hanna et al. proposed a 325 kb critical region for brain malformation and intellectual disability, comprising the DLL1 gene (OMIM 606582), PSMB1 (OMIM 602017), TBP (OMIM 600075), and PDCD2 (OMIM 600866) genes (Hanna et al., 2019). The key role of DLL1 is supported by cases with brain anomalies, intellectual disability and pathogenic variants in DLL1 gene. DLL1 gene is Notch ligand with an important role in development of the central nervous system (regulates neuronal differentiation), somites and lymphocytes (Striano et al., 2006; Peddibhotla et al., 2015; Fischer-Zirnsak et al., 2019; Hanna et al., 2019; Lesieur-Sebellin et al., 2022).

17q21.31 microdeletion

17q21.31 microdeletion known as Koolen-de Vries syndrome (KDVS) (OMIM 610443) is characterized by intellectual disability, hypotonia, suggestive facial dysmorphism (upslanting palpebral fissures, blepharophimosis, ptosis, epicanthus, a pear-shaped nose with bulbous nasal tip, and large/protruding ears), friendly behavior, brain anomalies (ventriculomegaly, ACC, hydrocephalus, Arnold-Chiari type 1 malformation), seizures, joint hypermobility, heart defects, and genitourinary anomalies. KDVS is caused by a 17q21.31 microdeletion or by a pathogenic variant in the KANSL1 gene (OMIM 612452). Genotype-phenotype correlation studies did not report significant clinical differences between microdeletions and pathogenic variant patients. The recurrent 17q21.31 microdeletion breakpoints map to flanking extensive low copy repeats suggesting that deletion is mediated by non-allelic homologous recombination. KANSL1 encodes the KAT8 regulatory NSL complex Subunit 1, a member of a histone acetyltransferase complex, which regulates global transcription (Koolen et al., 2008; Zollino et al., 2012; Koolen et al., 2016).

Monogenic disorders

Monogenic causes have been identified in 8–35% of ACC (Bedeschi et al., 2006; Schell-Apacik et al., 2008; Palmer and Mowat 2014; Ballardini et al., 2018; Morris et al., 2019). Advances in genetic sequencing technologies have enabled the discovery of pathogenic variants in a large number of genes: from those involved in development of callosal projections to genes encoding components of microtubules or metabolic enzymes (Table 2) (Schell-Apacik et al., 2008; Palmer and Mowat 2014; Ballardini et al., 2018; Morris et al., 2019).

Acrocallosal syndrome (ACS)

ACS (OMIM 200990) is a ciliopathy characterized by ACC, distal limb anomalies (postaxial polydactyly of the hands, and preaxial polydactyly of the feet), intellectual disability and facial dysmorphism (prominent forehead, hypertelorism, short nose with broad nasal bridge). In ACS the most frequent mutations were found in KIF7 gene (15q26.1) (OMIM 611254) while mutations of GLI3 gene (7p14.1) (OMIM 165240) are rare (Elson et al., 2002; Putoux et al., 2011). Both genes are involved in the ciliary sonic hedgehog (SHH) pathway. Depletion of proteins related to SHH pathway is associated with ciliogenesis defects. KIF7 gene encodes a member of kinesin motor proteins family, that localize from the base to the tip of the cilium and plays important roles in the regulation of microtubule acetylation and stabilization, and SHH signaling (Niceta et al., 2020). GLI3 gene encodes a zinc finger transcription factor, that interacts with microtubule associated MID1 protein and KIF7 and has a dual function: as a transcriptional activator and a repressor of SHH pathway (Laclef et al., 2015). Biallelic mutations in KIF7 gene have been reported in Hydrocephalus syndrome and rare cases of Joubert syndrome, with overlapping features, suggesting a continuous phenotypic spectrum. A severe phenotype is associated with KIF 7 gene truncating mutations, while missense KIF7 gene variants have been reported in milder cases (Putoux et al., 2011). Asadollahi et al. reported mutation in KIF7, SHH, and CPLANE1 genes in patients with suggestive facial dysmorphism for ACS and ciliopathy features (Asadollahi et al., 2018). Monoallelic mutations in GLI3 gene have been reported in Greig cephalopolysyndactyly and Pallister Hall syndromes. A group of ciliopathies associate intellectual disability and brain malformations, including ACC, highlighting the critical role for primary cilia in brain development (Valente et al., 2014; Arghir et al., 2021; Hasenpusch-Theil and Theil 2021).
Tubulinopathies

Tubulinopathies comprise a wide spectrum of brain malformations (lissencephaly, cerebellar hypoplasia, ACC, pachygyria, dysgyria), variable degree of motor and intellectual disabilities and epilepsy, caused by pathogenic variants in tubulin genes (α, β and γ isotypes) (Romero et al., 2018). The alpha and beta families of tubulin genes encode proteins which form heterodimers as fundamental components of microtubules. Tubulins interact with other proteins (e.g. β-III-tubulin connects with DCC in a netrin-1 dependent manner) and play key roles in neurogenesis, neuronal migration, cortical organization–pial basement membrane integrity, and also in axon guidance (Qu et al., 2013; Boyer and Gupton 2018). All mutations reported in TUBA1A (12q13.12, OMIM 602529), TUBB2B (6p25.2, OMIM 612850), TUBB3 (16q24.3, 602,661) and TUBB (6p21.33, 1919130) genes are heterozygote missense variants; this could suggest a dominant-negative effect. TUBA1A gene missense variants are the most frequent; some hot spots have been reported: Arg264 (c.790C>T, predominantly results in central pachygyria, whereas c.791G>A causes microlissencephaly with complete agenesis of the corpus callosum), Arg402 and Arg422 (Romaniello et al., 2015; Hebebrand et al., 2019).

FOXL1 syndrome (OMIM 613454), is a rare neurodevelopmental disorder, with a wide spectrum of features ranging from severe intellectual disability with poor or absent speech development, postnatal microcephaly, corpus callosum anomalies (agenesis/hypogenesis), delayed myelination, seizures, and dyskinesia, to deficient social interactions, disrupted circadian rhythm, and autistic traits. It has been previously classified as a congenital variant of Rett syndrome, due to clinical features and evolution, including a normal perinatal period followed by a phase of developmental regression at the age of 3–6 months. FOXL1 gene (OMIM 164874), located at 14q12, encodes the forkhead box protein G1, a conserved transcriptional repressor, that play a critical role in forebrain development, from the timing of neurogenesis, to the patterning of the cerebral cortex and callosal projections. FOXL1 gene truncating mutations (frameshift or nonsense) in the N-terminal domain and 14q12 microdeletions associate a severe phenotype, while FOXL1 gene missense mutations in the forkhead domain lead to milder phenotype (Kortum et al., 2011; Leonbroni et al., 2018; Mitter et al., 2018; Hou et al., 2020; Akol et al., 2022).

ACC–Neuropathy syndrome (Andermann syndrome)

Hereditary motor and sensory neuropathy with ACC (OMIM 218000) is a channelopathy characterized by severe progressive sensorimotor neuropathy with resulting hypotonia, areflexia, and amyotrophy, and by dysgenesis of the corpus callosum. Common features include intellectual and developmental delays, psychiatric manifestations (paranoid elements, depression, hallucinations), progressive scoliosis and facial dysmorphism (palpebral ptosis, hypertelorism, hypoplastic maxilla, high-arched palate). It is inherited in an autosomal recessive manner, and the high incidence in the Saguenay and Lac-Saint-Jean regions of Quebec, Canada, due to the c.2436+1delG mutation in SLC12A6 gene (OMIM 604878) suggest a founder effect. SLC12A6 gene, located at 15q14, encodes a solute carrier family 12 member 6 (KCC3), a potassium chloride cotransporter, expressed in the peripheral and central nervous system. Impaired KCC3 function alters maintenance of homeostasis of the membrane threshold, leading to neuronal degeneration. A case with a gain of function mutation and peripheral neuropathy but no corpus callosum abnormalities has been reported (Gauvreau et al., 1993; Kahle et al., 2016; Flores et al., 2019).

Aicardi syndrome

Aicardi syndrome (OMIM 304050) is characterized by a triad of features: agenesis or hypogenesis of corpus callosum, chorioretinal lacunae, and infantile spasms. Other common findings include: perrinventricular and subcortical heterotopia, intracranial cysts, polymicrogyria, retinal and optic nerve colobomas, microphthalmia, costovertebral anomalies, gastrointestinal disorders (reflux, constipation, feeding difficulties) and suggestive facial dysmorphism (prominent premaxilla, upturned nasal tip, decreased angle of the nasal bridge, and sparse lateral eyebrows). It affects usually females, but the disease was identified in few cases with Klinefelter syndrome (47, XXY) or 46, XY males with profound microcephaly. The inheritance of Aicardi syndrome is considered X-linked dominant with early embryonic lethality in the majority of hemizygous males. Skewed X chromosome inactivation and translocations involving Xp22 have been reported in several cases but a candidate gene has not been identified. Nemos et al. excluded mutations in the CDKL5 gene (Xp22.13) (OMIM 300203) (Ebbé et al., 2009; Nemos et al., 2009; Wong and Sutton 2018).

Corpus callosum agenesis - Abnormal genitalia syndrome (Proud syndrome)

Corpus callosum agenesis - abnormal genitalia syndrome (OMIM 300004) is characterized by ACC, neurological manifestations (intellectual disability, developmental delay, epilepsy, spasticity), and urogenital anomalies (hypospadias, cryptorchidism, renal dysplasia). It is part of a broad phenotypic spectrum of disorders caused by mutation in the ARX gene (OMIM 300382), ranging from lissencephaly to ACC with abnormal genitalia to developmental and
epileptic encephalopathy without brain malformations to syndromic and nonsyndromic X-linked intellectual disability. ARX gene, located at Xp22.13, encodes a transcription factor which belongs to the class of homeobox proteins. ARX participate to fundamental processes of brain development: patterning, neuronal proliferation and migration, cell maturation and differentiation, axonal outgrowth and connectivity. ARX contains several domains, including the homeobox domain, a PRD-like domain, a N-terminal octapeptide domain, a central acidic domain, a C-terminal aristaless domain, as well as three nuclear localization sequences and four polyalanine tracts. Premature termination mutations and missense mutations in the homeodomain or nuclear localization sequences are associated with severe phenotype involving brain malformations. Missense mutations outside of the homeobox domain or expansions in the polyalanine tracts lead to milder phenotype without brain malformation. Usually, males are severely affected, and heterozygous females may be unaffected or have a milder phenotype (Kato et al., 2004; Friez et al., 2006; Olivetti and Noebels 2012; Ghadami and Eshaghkhani 2019; Leung et al., 2022).

Pyruvate dehydrogenase complex (PDC) deficiency

PDC deficiency (OMIM 312170, 614111, 245348, 245349, 246904, 608782) is an inborn error of mitochondrial energy metabolism, with a wide phenotypic spectrum ranging from fatal neonatal lactic acidosis to neurological manifestations with structural brain abnormalities. ACC is found in over one-third of patients with PDHA1 gene mutations (Pavlut-Pereira et al., 2020; Savvidou et al., 2022). The disorder can result from mutations in multiple genes that encode components of the PDC. PDHA1 (Xp22.1) (OMIM 300502), PDHB (3p14.3) (OMIM 179060), DLAT (11q23.1) (OMIM 608770), PDHX (11p13) (OMIM 608769), DLD (7q31.1) (OMIM 238331) and PDP1 (8q22.1) (OMIM 605993). The most common are mutations in the PDHA1 gene, which encodes E1 alpha subunit, and has eleven exons. Frameshift PDHA1 gene mutations occur preferentially in exons 10 and 11, associate a very low enzyme activity and severe phenotype. Missense PDHA1 gene mutations are located usually in exons one to nine and are more prevalent in males. Hemizygous males are generally symptomatic and more severely affected (with significant lethality in infancy) whereas heterozygous females present variable clinical manifestations and greater survival due to random patterns of X-inactivation (Patel et al., 2012; Horga et al., 2019; Pavlu-Pereira et al., 2020).

Pyridoxine-dependent epilepsy (PDE)

PDE (OMIM 266100) is characterized by recurrent seizures, usually with early onset, resistant to standard anticonvulsants but with clinical and electroencephalogram (EEG) improvement following pyridoxine supplementation. Intellectual disability is common (75%–80%) and does not correlate with seizure control or age at treatment initiation (Gospe et al., 2021; Coughlin et al., 2019). Callosal abnormalities are the most frequent neuroimaging findings and are not explained by treatment lag (Tolto et al., 2018; Tseng et al., 2022). PDE is caused by mutation in ALDH7A1 gene (OMIM 107323), located on 5q23.2, which encodes alpha-aminoadipic semialdehyde (α-AASA) dehydrogenase, a key enzyme in lysine metabolism. The enzyme deficiency, inherited in an autosomal recessive manner, leads to accumulation of α-AASA, piperic acid, and Δ-1-piperideine-6-carboxylate, responsible for sequestration of pyridoxal-5-phosphate. Missense mutations are the most common and are more frequent in exons 5 and 6 (within the linker domain), 10 (within the NAD binding domain), 15 (within the catalytic domain). The most prevalent mutation is c.1279G>C (p.Glu427Gln) and homozygous patients present variable phenotype with neonatal or late-onset. Splice site (e.g. c.834G>A), frameshift and nonsense mutations have been also reported (Coughlin et al., 2019). The deep intron mutation c.696–502G>C results in the usage of two cryptic splice sites and introduction of a pseudoexon between exons 7 and 8 (Mich et al., 2012). Coughlin et al. hypothesized that some mutations affect not only the enzyme activity but also the stability or the ability to reach its targeted environment (Coughlin et al., 2019).

Congenital mirror movements (CMM)

CMM (OMIM 157600) is characterized by early onset, involuntary movements of one side of the body that mirror intentional movements on the opposite side. Physiologic mild mirror movements are occasionally found in young children, but their persistence beyond the age of 7 years is pathologic. CMM usually persist throughout life and involve predominantly the upper limbs, more severe distal (Meneret et al., 2014). Monoallelic truncating (frameshift and nonsense) mutations of DCC gene (OMIM 120470) are associated with CMM. Missense mutations c.2378T>G (p.Val793Gly) and c.2414G>A (p.Gly805Glu), located within the NTN1 binding interface are also associated with CMM. Monoallelic DCC gene mutations are associated with variable expressivity and incomplete penetrance. The DCC gene, located at 18q21.2, encodes a functional receptor for netrin (NTN1), a transmembrane glycoprotein belonging to the immunoglobulin (Ig) superfamily of cell adhesion molecules. DCC plays a key role in the transduction of NTN1-induced attractive and repulsive signaling in the coordinated outgrowth and guidance of commissural axons that cross the anatomical midline of the body. Corticospinal axons and callosal axons use slightly different signaling pathways, and a DCC mutation may differentially affect commissural versus subcerebral axon trajectories, explaining the variable phenotypes: mirror movements, ACC, or both (Srour et al., 2010; Marsh et al.,
2018). CMM is also caused by monoallelic mutation in NTN1 gene (17p13.1) (OMIM 601614), RAD51 gene (15q15.1) (OMIM 179617) and biallelic mutations in DNAI4 gene (22q13.1) (OMIM 610565), but no callosal anomalies have yet been reported (Ahmed et al., 2014; Meneret et al., 2014).

**Horizontal gaze palsy with progressive scoliosis (Split brain syndrome) (OMIM 617542)**

Biallelic, DCC gene mutations lead to a complex syndrome associated with a broad disorganization of white-matter tracts throughout the CNS (Jamuar et al., 2017). The features include absence of all commissures (including the CC, anterior and posterior), brainstem defects (including hypoplasia of the pons and midbrain), horizontal gaze palsy, impaired intellectual development and progressive scoliosis. Biallelic mutations are associated with complete penetrance (Jamuar et al., 2017; Marsh et al., 2018). Biallelic mutation in ROBO3 gene (11q24.2) (OMIM 608630), which encodes a coreceptor of NTN1, leads to horizontal gaze palsy with progressive scoliosis and brainstem defects (hypoplasia of the pons and cerebellar peduncles, butterfly configuration of the medulla, and pontine cleft in the midline); no CC anomalies have been reported. ROBO3 is a member of the roundabout family of receptors, inhibits ROBO1/2, interacts with DCC and potentiate commissural axonal outgrowth and attraction (Jen et al., 2004; Pinero-Pinto et al., 2020).

**Septo-optic dysplasia (SOD)**

SOD (OMIM 182230) is characterized by a clinical triad of optic nerve hypoplasia, dysfunction of the hypothalamic-pituitary axis, and midline brain abnormalities, including agenesis of the septum pellucidum and CC. For a SOD spectrum diagnosis, a combination of any two of the three features is required. Only 30%–47% of patients present the complete classical triad. Additional findings include developmental delay, seizures, cerebral palsy, autism, sleep disorders, thermoregulatory disturbances, hearing loss, anosmia, and heart defects. Associated brain abnormalities (hydrocephalus, polymicrogyria, grey matter heterotopias) have also been reported (sometimes referred to as SOD-plus syndrome) (Webb and Dattani 2010; Ganau et al., 2019; Ward et al., 2021). SOD is usually sporadic but familial cases with intrafamilial variability have been reported. Genetic abnormalities have been identified in <1% of the patients. Homozygous or heterozygous mutations in HESX1 (3p14.3) (OMIM 601802) have been described in patients with variable phenotypes ranging from isolated growth hormone deficiency to SOD. HESX1 encodes a paired-like homeobox transcription factor, which acts as a transcriptional repressor and is essential for normal forebrain and pituitary development. Heterozygous HESX1 mutations are associated with a milder phenotype and incomplete penetrance (Kelberman and Dattani 2008; Webb and Dattani 2010; Fang et al., 2016). Mutations in other genes involved in the regulation of the Wnt/β-catenin signaling pathway have been reported in SOD cases: SOX2 (3q26.33) (OMIM 184429), SOX3 (Xq27.1) (OMIM 313430), OTX2 (14q22.3) (OMIM 600037), TCF7L1 (2p11.2) (OMIM 604652) or TAX1BP3 (17p13.2) (OMIM 616484). SOX2 mutations are associated with severe eye abnormalities, and additional features (genital anomalies, esophageal atresia, intellectual disability, seizures) (Blackburn et al., 2018). SOX3 duplications/point mutations have been reported in cases with hypopituitarism and/or intellectual disability (Arya et al., 2019; Li et al., 2022). OTX2 pathogenic variants are associated with hypopituitarism and eye abnormalities and incomplete penetrance (Gregory et al., 2021). Mutations in genes involved in hypogonadotropic hypogonadism with or without anosmia (OMIM 612702) - FGFR1 (8p11.23) (OMIM136350) and FGF8 (10q24.32) (OMIM 600483) have also been described in SOD patients suggesting a genetic overlap (Raivio et al., 2012). The etiology of SOD remains unclear in the majority of patients; vascular abnormalities, teratogens, and young maternal age may also be involved (Ganau et al., 2019).

**Isolated ACC**

The genetic causes of isolated ACC appear more elusive but some pathogenic variants in genes associated with syndromic ACC have been reported. DCC gene missense mutations, located within the NTN1 binding sites (in fourth, fifth and sixth fibronectin type III-like domains), are associated with isolated ACC, in females. Marsh et al. observed a significant dose-dependent increase in DCC gene expression in testosterone-treated neural stem cells derived from human embryonic stem cells and suggested that isolated ACC may occur when DCC gene expression is below a critical level during CC development. Jouan et al. identified compound heterozygous missense variants in the CDK5RAP2 gene (OMIM 608201) in 3 sibs with isolated ACC. The CDK5RAP2 gene, located at 9q33.2, encodes cyclin-dependent kinase 5 regulatory subunit 2 (CDK5RAP2) a pericentriolar structural protein that has a major role in the microtubule-organizing function of the centrosome through interaction with the γ-tubulin ring complex. Its expression is particularly high within the brain, especially within the thalamus and corpus callosum (Jouan et al., 2016). These findings suggested that alteration of CDK5RAP2 activity may dysregulate neurogenic cell divisions. Biallelic mutations in CDK5RAP2 are associated with autosomal recessive primary microcephaly and isolated ACC. Jouan et al. hypothesized that mutations with residual
function may lead to isolated ACC, while severe loss-of-function variants (nonsense, splice site, truncating missense) may result in severe microcephaly with reduced brain size and concomitantly with partial or complete ACC (Jouan et al., 2016). The factors determining the phenotypic variability are complex and include the type and location of mutation and possible genetic modifiers (Jouan et al., 2016; Marsh et al., 2018).

The large number of partial chromosomal anomalies and monogenic syndromes associated with ACC illustrate the high genetic heterogeneity (Figure 1).

**Prognosis**

In isolated ACC, neurodevelopmental outcomes range from normal development in about 64.8–75% of the individuals to different levels of intellectual disability, including severe (in 12% of cases) (D’Antonio et al., 2016; Bernardes da Cunha et al., 2021). Sleep disturbances are also common and include: greater sleep onset delay, decreased sleep duration, sleep anxiety, night wakings, parasomnias, sleep-disordered breathing, daytime sleepiness, increased slow-wave sleep, more distressful dreams, and narcolepsy (Ingram and Churchill 2017; Yates et al., 2018). Regular
follow-up is necessary because some cases with initial “normal development” presented subtle speech, attention, and reasoning difficulties with increasing age. In a significant percentage of cases (approximately 40%) with ACC, social and behavioral problems have been reported: emotional immaturity, impaired social competence, deficits in planning, and poor communication of emotions (Wegiel et al., 2017). While autistic elements have been reported in cases with ACC, MRI in patients with autism revealed thinning of corpus callosum but further studies are necessary to elucidate the connection between corpus callosum anomalies and autism (Frazier and Hardan 2009; Paul et al., 2014; Hofman et al., 2020). Other adverse outcomes related to ACC include epilepsy, visual problems and psychiatric disorders (schizophrenia) (Popoola et al., 2019). The rate of severe disability in cases with associated anomalies is higher than that in patients with isolated ACC. The spectrum of neurodevelopmental outcome depends on several factors, such as the extension of the ACC (complete or partial), the presence and severity of associated defects, as well as on the magnitude of residual interhemispheric transfer through other commissures (Guadarrama-Ortiz et al., 2020). A checklist of suggested diagnostic evaluations in a postnatal patient with ACC is summarized in Table 3.

The variable neurodevelopmental outcomes of ACC make prenatal counseling a challenge. Fetal MRI plays a critical role in detection of associated anomalies, a major prognosis determinant (Bernardes da Cunha et al., 2021). Some studies reported discrepancy between prenatal diagnosis of isolated ACC and postnatal or postmortem diagnosis of additional anomalies (5% in complete ACC and 15% in partial ACC). These discrepancies may be related to the technology, method of diagnosis, or to the timing of investigations because some anomalies may be identified only in the third trimester of pregnancy (Paladini et al., 2013; Griffiths et al., 2017; Leombroni et al., 2018).

Prenatal genetic diagnosis is essential in these cases. Chromosomal abnormalities (except mosaicism if abnormal cells are not present in the examined specimen) and an increasing number of monogenic disorders can be diagnosed prenatally. Conventional prenatal karyotype identifies complete or large partial aneuploidies in 4.8%–7.5% of ACC (Leombroni et al., 2018). Prenatal chromosomal microarray analysis (CMA) in cases with normal karyotype reveals pathological copy number variations in 5.7–6.9% of ACC (Greenbaum et al., 2021). However, the diagnostic rate of fetal karyotype and CMA does not exceed 15–20%, because monogenic causes have the highest frequency. In this context, many studies highlighted the utility of WES in determining the genetic etiology of CCA including in prenatal cases. The detection rate is higher in cases with associated anomalies. WES can also detect many copy number variations. Gene variant interpretation could be challenging due to incomplete prenatal phenotype (Reches et al., 2018; Heide et al., 2020; Lei et al., 2021; She et al., 2021).

Conclusion

Intensive research over the last decade has highlighted the genetic heterogeneity of ACC, which reflects the complexity of CC development. Although an impressive number of chromosomal abnormalities and gene mutations have been reported in ACC-associated syndromes, there are still conditions of unclear etiology. Incomplete penetrance and variable expressivity, unexplained by the type of mutation, suggest the existence of genetic modifiers. Detection of associated anomalies and genetic causes is essential in prenatal detected cases, given the variable outcome, oscillating between the normal cognitive level and severe psychomotor delay. WES alone or simultaneous, WES and CMA may be considered a first-tier test in the prenatal diagnosis of ACC given the frequency of monogenic and chromosomal anomalies and the time constraints. The elucidation of all molecular mechanisms of ACC and the genotype-phenotype correlations will aid in understanding of CC role and in development of personalized management.

Author contributions

All authors contributed equally to this paper. MP, SP, AL wrote the initial manuscript, CG, VL, VG reviewed and improved the article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
All claims expressed in this article are solely by the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Ahmed, I., Mittal, K., Sheikh, T. I., Vasi, N., Rafaq, M. A., Makhailov, A., et al. (2014). Identification of a homoygous splice site mutation in the dynein axonomal light chain 4 gene on 22q13.1 in a large consanguinouse family from Pakistan with congenital mirror movement disorder. *Hum. Genet.* 133 (11), 1419–1429. doi:10.1007/s00439-014-1475-8

Akol, I., Vogel, F. T., and Vogel, T. (2022). Paving therapeutic avenues for FOXG1 syndrome: Untangling genotypes and phenotypes from a molecular perspective. *Jms* 23 (2), 954. doi:10.3939/jms2302954

Aghar, A., Popescu, R., Resmirta, I., Budisutanto, M., Baturau, L. I., Gorduza, E. V., et al. (2021). Pallister-kilian syndrome versus trisomy 12p: A clinical study of 5 new cases and a literature review. *Genet 12* (6), 811. doi:10.3939/gene20060811

Aarya, V. B., Chawda, G., Nambisan, A. K. R., Mohi-Usdin, N., Vamsakuti, E., Ajzenstejn, M., et al. (2019). Xq27.1 duplication encompassing SOX3: Variable phenotype and smallest duplicated association with hypotopituitarism to date - a large case series of unrelated patients and a literature review. *Horm. Res. Paediat.* 92 (4), 382–389. doi:10.1159/000503784

Asadollahi, R., Strauss, J. E., Zenker, M., Beuing, O., Edvardson, S., Elpeleg, O., et al. (2018). Clinical and experimental evidence suggest a link between KIF7 and neurodevelopmental outcomes following prenatal diagnosis of isolated agenesis of the corpus callosum. *Pediatrneurol.* 2005.08.008

Battaglia, M. A., et al. (2006). Agenesis of the corpus callosum: Clinical and genetic aspects. *Clin. Genet.* 70 (3), 369–379. doi:10.1111/j.1399-0004.2006.00419.x

Balladini, E., Marino, P., Maietti, E., Neville, G. A. J., and Neville, A. J. (2018). Prevalence and associated factors for agenesis of corpus callosum in Emilia Romagna (1981-2015). *Eur. J. Med. Genet.* 61 (9), 524–530. doi:10.1016/j.ejmg.2018.06.004

Ballef, B. C., Rosenfeld, J. A., Traylor, R., Theisen, A., Bader, P. I., Ladda, R. L., et al. (2012). High-resolution array CGH defines critical regions and candidate genes for microcephaly, abnormalities of the corpus callosum, and seizure phenotypes in patients with microdeletions of 1q43q44. *Hum. Genet.* 131 (1), 145–156. doi:10.1007/s00439-011-1073-y

Bedeschi, M. F., Bonaglia, M. C., Grasso, R., Pellegri, A., Garghentino, R. R., Battaglia, M. A., et al. (2006). Agenesis of the corpus callosum: Clinical and genetic study in 63 young patients. *Pediatr. Neurol.* 34 (3), 186–193. doi:10.1016/j.pedinneurol.2005.08.008

Bernardes da Cunha, S., Carneiro, M. C., Miguel Sa, M., Pina, A. C., and Pina, C. (2021). Neurodevelopmental outcomes following prenatal diagnosis of isolated corpus callosum agenesis: A systematic review. *Fetal Diagn Ther.* 48 (2), 88–95. doi:10.1159/0005012534

Blackburn, P. R., Chacon-Camacho, O. F., Ortiz-González, X. R., Reyes, M., Lopez-Uriarte, G. A., Zarei, S., et al. (2018). Extension of the mutational and clinical findings of 1q43q44 linked intellectual disability. *Front. Cell. Neurosci.* 12, 221. doi:10.3389/fncel.2018.00221

Cargnin, F., Kwon, J. S., Katzman, S., Chen, B., Lee, J. W. S. K., and Lee, S. K. (2018). FOXG1 orchestrate neocortical organization and cortico-cortical connections. *Neuron* 100 (5), 1083–1096. doi:10.1016/j.neuron.2018.10.016

Cohen, J. S., Srivastava, S., Farwell Hagman, K. D., Shinde, D. N., Huether, R., Darcy, D., et al. (2017). Further evidence that nucleosomess and truncating variants inZBTB18cause intellectual disability with variable features. *Clin. Genet.* 91 (5), 697–707. doi:10.1111/cge.12861

Coughlin, C. R., Spector, E., Meeks, N. J. L., Kronquist, K. E., Aslamy, M., Wempe, M. F., et al. (2019). The genetic footprint of the ALDH7A1 mutations resulting in pyridoxine dependent epilepsy: A common epileptic encephalopathy. *J. Inherit. Metab. Dis.* 42 (2), 353–361. doi:10.1007/s10545-012-1045-5

D’Antonio, F., Pagani, G., Familiaru, A., Khalil, A., Sages, T. L., Malinger, G., et al. (2016). Outcomes associated with isolated agenesis of the corpus callosum: A meta-analysis. *Pediatri 138* (3), 445. doi:10.1542/peds.2016-0455

de De-Smudder, C. E., Engelen, J. J., Schrauder-Stumpel, C. T., Govaerts, L. C., de Vries, B., Vles, J. S., et al. (1995). Inversion duplication of the short arm of chromosome 8: Clinical data on seven patients and review of the literature. *Am. J. Med. Genet.* 59 (3), 369–374. doi:10.1002/ajmg.130509318
malformations in 6q27 microdeletions.

Yonath, H., et al. (2021). Chromosomal microarray analysis in pregnancies with 1159/000501008 callosum: Contribution to further diagnostic delineation. s13023-019-1020-x doi:10.3389/fcell.2021.630161

female monozygotic twin pair.

625. doi:10.3390/brainsci10090625

syndrome.

doi:10.3389/fneur.2019.00035

Roles of slit-robo signaling in neocortical formation.

corpus callosum development in BALB/cAJ mice. PLoS One

M., et al. (2019). PlexinA1 is crucial for the midline crossing of callosal axons during development during postnatal life: A case report and review of the literature. J Med Case Rep. 14 (1), 28. doi:10.1186/s13256-020-2359-2

Hanna, M. D., Moretti, P. N., de Oliveira, S. F., Pic-Taylor, A., and F. Mazzen, J. (2019). Defining the critical region for intellectual disability and brain malformations in 6q27 microdeletions. Mol. Syndromol. 10 (4), 202–208. doi:10.1080/16091402.2019.1568254

Hasenpusch-Thiel, K., and Theil, T. (2021). The multifaceted roles of primary cilia in the development of the cerebral cortex. Front. Cell Dev. Biol. 9, 630161. doi:10.3389/fcell.2021.630161

Hebebrand, M., Hüffmeier, U., Trollmann, R., Hehr, U., Uebe, S., Ekici, A. B., et al. (2019). The mutational and phenotypic spectrum of TUBA1A-associated tubulopathy. Orphanet J Rare Dis. 14 (1), 38. doi:10.1186/s13023-019-1020-x

Heide, S., Spentchian, M., Valence, S., Buratti, J., Mach, C., Lejeune, E., et al. (2010). Noninvasive detection of the distinction between progressive and statical brain malformations in 6q27 microdeletions. Mol. Syndromol. 1 (4), 202–208. doi:10.1080/16091402.2010.506008

Hofman, J., Hutny, M., Paprocka, K. J., and Paprocka, J. (2020). Corpus callosum agenesis: An insight into the etiology and spectrum of symptoms. Brain Sci. 10 (9), 625. doi:10.3390/brainsci10090625

Horga, A., Woodward, C. E., Mills, A., Pareés, I., Hargreaves, I. P., Brown, R. M., Glass, H. C., Shaw, G. M., Sherr, C. E. H., and Sherr, E. H. (2008). Agenesis of the corpus callosum, and developmental split brain syndrome. J Med Genet. 45 (11), 710–720. doi:10.1136/jmg.2008.058701

Kortum, F., Das, S., Flindt, M., Morris-Rosendahl, D. J., Stefanova, I., Goldstein, A., et al. (2011). The core FOXG1 syndrome phenotype consists of postnatal microcephaly, severe mental retardation, absent language, dyskinesia, and corpus callosum hypogenesis. J Med. Genet. 48 (6), 596–406. doi:10.1136/jmedgenet.2010.087528

Ku, R. Y., and Torii, M. (2020). New molecular players in the development of callosal projections. Cells 10 (1), 29. doi:10.3390/cells10010029

Laclaf, C., Anselme, J., Besse, L., Catala, M., Palmyre, A., Baas, D., et al. (2015). The role of primary cilia in corpus callosum formation is mediated by production of the Gli3 repressor. Hum. Mol. Genet. 24 (17), 4997–5014. doi:10.1093/hmg/ddv221

Lei, L., Xiong, L. J.-j., and Xiong, J. J. (2021). Whole-exome sequencing increases the diagnostic rate for prenatal fetal structural anomalies. Eur. J. Med. Genet. 64 (9), 104288. doi:10.1016/j.ejmg.2021.104288

Leifeld, P. H., Gooskens, R. H., Tulleken, C. A., Regli, L., Uitterlinden, C. A., Han, K. S., et al. (2010). Noninvasive detection of the distinction between progressive and compensated hydrocephalus in infants: Is it possible? Ped 5 (6), 562–568. doi:10.3171/2010.2.PEDS09309

Leombroni, M., Khalil, A., D’Antonio, M. F., and D’Antonio, F. (2018). Fetal midline anomalies: Diagnosis and counselling Part I: Corpus callosum anomalies. Eur. J. Paediatr. Neurology 22 (6), 951–962. doi:10.1016/j.ejpn.2018.08.007

Lesieur-Sebeline, M., Tillin, M., Khou Van Kien, P., Herve, B., Bourgon, N., Dupont, C., et al. (2022). Terminal 6q deletions cause brain malformations, a phenotype mimicking heterozygous DLL1 pathogenic variants: A multicenter retrospective case series. Prenat. Diag. 42 (1), 118–135. doi:10.1002/pd.6674

Leung, R. F., George, A. M., Rosaud, E. M., Faux, M. C., Eisenstat, J. T. D. D., and Eisenstat, D. D. (2022). Genetic regulation of vertebrate forebrain development by homeobox genes. Front. Neurosci. 16, 843794. doi:10.3389/fnins.2022.843794

Li, J., Zhong, Y., Guo, T., Li, Y. J., and Li, J. (2022). Case report: A novel point mutation of SOX3 in a subject with growth hormone deficiency, hypogonadotropic hypogonadism, and borderline intellectual disability. Front. Endocrinol. 13, 801375. doi:10.3389/fendo.2022.801375

Marsh, A. P. L., Edwards, T. J., Galea, C., Cooper, H. M., Engle, E. C., Iamaa, S. S., et al. (2018). DCCmutant update: Congenital mirror movements, isolated agenesis of the corpus callosum, and developmental split brain syndrome. Hum. Mutat. 39 (1), 23–39. doi:10.1002/humu.23361

McCafferty, W. K., Ortilz-Londono, C. F., Mathew, T. K., Hoang, K., Chen, S. B., and Chen, B. (2015). Mutual regulation between Satb2 and Fezf2 promotes subcerebral homeobox genes. Front. Neurosci. 9, 630161. doi:10.3389/fnins.2015.0630161

Mol. Syndromol.
Agenesis of the fetal corpus callosum: Sonographic signs change with advancing approach to diagnosis.

Pânzaru et al. 10.3389/fgene.2022.958570

Brian malformations associated to Aldh7a1 gene mutations: Report of a novel mutation in a continuum of fragility of the region.

Shigematsu, T., et al. (2012). A network of genetic repression and derepression specific projection fates in the developing neocortex.

Kotsuki, A., Kikuchi, M., Takeda, M., Nishiyama, Y., and Okazaki, T. (2012). Heterogeneity of functional connectivity in idiopathic autism.

Shen, Q., Tang, E., Peng, C., Wang, L., Tan, D. W., and Tan, W. (2021). Prenatal genetic testing in 19 fetuses with corpus callosum abnormality. J. Clin. Lab. Anal. 35 (11), e23971. doi:10.1002/jcla.23971

Srinivasan, K., Leone, D. P., Bateson, R. K., Dobrevia, G., Kohwi, Y., Kohwi-Shigematsu, T., et al. (2012). A network of genetic repression and derepression specific projection fates in the developing neocortex.

Srinivasan, K., Leone, D. P., Bateson, R. K., Dobrevia, G., Kohwi, Y., Kohwi-Shigematsu, T., et al. (2012). A network of genetic repression and derepression specific projection fates in the developing neocortex.

Stoll, C., Roth, B. M. P., and Roth, M. P. (2019). Associated anomalies in cases with agenesis of the corpus callosum. Am. J. Med. Genet. 179 (10), 2101–2111. doi:10.1002/ajmg.a.33558

Srivastava, N., Georgiev, G., Kóbor, J., Bereg, E., Szirha, L. S., and Szirha, L. (2011). Corpus callosum anomalies: Birth prevalence and clinical spectrum in Hungary. Pediatr. Neurol. 44 (6), 420–426. doi:10.1016/j.pediatrneurol.2011.01.002

Srinivasan, K., Leone, D. P., Bateson, R. K., Dobrevia, G., Kohwi, Y., Kohwi-Shigematsu, T., et al. (2012). A network of genetic repression and derepression specific projection fates in the developing neocortex.

Stein, L. A., Teela, L., Janssen, M. C., Bok, L. A., Willemsen, M. A. P. A., Neuteboom, R. F., et al. (2022). Pyridoxine-dependent epilepsy (PDE-ALDH7A1) in adulthood: A Dutch pilot study exploring clinical and patient-reported outcomes. Mol. Genet. Metabolism Rep. 31, 100853. doi:10.1016/j.ymgmr.2022.100853

Valente, E. M., Rooti, R. O., Glessen, E. G., and Glessen, J. G. (2014). Primary cilia in neurodevelopmental disorders. Nat. Rev. Neurol. 10 (1), 27–36. doi:10.1038/nn.3427

Wang, B., Li, H., Mutlu, S. A., Bowser, D. A., Moore, J. M., Wang, M. C., et al. (2017). The amyloid precursor protein is a conserved receptor for Slit to mediate axon guidance. eNeuro 4 (3), 0185-17.2017. doi:10.1523/ENEURO.1851-17.2017

Webb, E. A., and Dattani, M. T. (2010). Septo-optic dysplasia. Eur. J. Hum. Genet. 18 (4), 393–397. doi:10.1038/ejhg.2009.125

Wegiel, J., Floiry, M., Kaczmierski, W., Brown, W. T., Chadman, K., Wisniewski, T., et al. (2017). Partial agenesis and hypoplasia of the corpus callosum in idiopathic autism. J. Neuropathol. Exp. Neurol. 76 (3), 225–237. doi:10.1093/jnen/nlx003

Wese, J., Beckmann, M., Bahhaim, H., Ittermann, T., Allenberg, H., Domanski, G., et al. (2019). Analysis of pathological cranial ultrason sound findings in neonates that fall outside recent indication guidelines: Results of a population-based birth cohort: Survey of neonates in pommerania (SNIP-study). BMC Pediatr. 19 (1), 476. doi:10.1186/s12887-019-1843-6

Wong, B. K. Y., and Sutton, V. R. (2018). Aicardi syndrome, an unolved mystery: Review of diagnostic features, previous attempts, and future opportunities for genetic examination. Am. J. Med. Genet. 178 (4), 423–431. doi:10.1002/ajmg.c.31658

Yeates, J. F., Ingram, M. D. M. G., and Ingram, D. G. (2018). Sleep in children with congenital malformations of the central nervous system. Curr. Neurol. Neurosci. Rep. 18 (7), 38. doi:10.1007/s12028-018-0850-6

Zollino, M., Orteschi, D., Murdolo, M., Battaglia, D., Stefanini, C., et al. (2012). Mutations in KANSL1 cause the 17q21.31 microdeletion syndrome. Am. J. Hum. Genet. 90 (1), 182–197. doi:10.1016/j.ajhg.2012.03.017

Zoller, T. W., Subramony, S. H., Stacpoole, J. P. W., and Stacpoole, W. P. (2012). The spectrum of pyruvate dehydrogenase complex deficiencies. J. Inherit. Metab. Dis. 35 (2), 248–263. doi:10.1016/j.jimd.2012.03.017

Zollino, M., Orteschi, D., Murdolo, M., Battaglia, D., Stefanini, C., et al. (2012). Mutations in KANSL1 cause the 17q21.31 microdeletion syndrome. Am. J. Hum. Genet. 90 (1), 182–197. doi:10.1016/j.ajhg.2012.03.017

Zollino, M., Orteschi, D., Murdolo, M., Battaglia, D., Stefanini, C., et al. (2012). Mutations in KANSL1 cause the 17q21.31 microdeletion syndrome. Am. J. Hum. Genet. 90 (1), 182–197. doi:10.1016/j.ajhg.2012.03.017